Cytodyn INC 8-K filings

CytoDyn announced promising early clinical results for leronlimab in metastatic colorectal cancer and outlined its 2026 development strategy.

CytoDyn Inc. announced the extension of two secured convertible promissory notes totaling $57 million by 36 months, coupled with a reduced annual interest rate and monthly stock payments.

CytoDyn Inc. announced multiple unregistered sales of equity securities and warrants, raising approximately $18.8 million in cash and converting $1.5 million in debt to equity.

CytoDyn Inc. has reached an agreement in principle to settle a securities class action lawsuit for $500,000 in cash and 49 million shares of common stock.

CytoDyn Inc. stockholders approved an increase in authorized common stock and re-elected its board of directors at the 2025 Annual Meeting.

CytoDyn Inc. has secured a $30 million standby equity purchase agreement with Yorkville Advisors Global, providing flexible capital for working capital and general corporate purposes.

CytoDyn Inc. replaces its independent auditor, Marcum LLP, with CBIZ CPAs P.C. after Marcum's attestation business was acquired and Marcum subsequently resigned.

CytoDyn Inc. appoints Robert E. Hoffman as its new Chief Financial Officer, effective May 15, 2025, succeeding interim CFO Mitch Cohen.

CytoDyn Inc. held its 2024 Annual Meeting of Stockholders on November 22, 2024, where all director nominees were elected, the appointment of Marcum LLP as the independent auditor was ratified, and executive compensation was approved on an advisory basis.

CytoDyn has reached a settlement with Amarex Clinical Research, resulting in a $12 million payment to CytoDyn and the elimination of $14 million in debt.

CytoDyn Inc. has replaced its independent auditor with Marcum LLP, effective immediately, for the fiscal year ending May 31, 2024, and subsequent quarterly reviews.

CytoDyn Inc. reported unregistered sales of equity securities exceeding 5% of outstanding shares, primarily through private placements of common stock and warrants.

CytoDyn Inc. has dismissed its independent auditor, BF Borgers CPA PC, after the SEC permanently barred the firm from practicing before the commission.

CytoDyn has reached an agreement with Samsung BioLogics to restructure its debt and wind down manufacturing services, shifting to other providers.

CytoDyn Inc. disclosed unregistered sales of equity securities exceeding 5% of outstanding shares, primarily through a private placement and convertible note exchanges.

CytoDyn has appointed Jacob Lalezari as CEO and Mitchell Cohen as interim CFO, effective January 26, 2024 and February 1, 2024 respectively, following a leadership transition.